Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.

Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.

Abstract: The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.

Abstract: The present invention provides a nucleic acid, or an immunogenic composition thereof, that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof. The present invention also provides methods for triggering an immune response in a cat and methods for treating or preventing a tumor in a cat using the immunogenic composition of the invention.

Abstract: The present invention relates to methods for transferring a nucleic acid in vivo into skin cells wherein the nucleic acid is injected by intradermal (ID) injection and is electrically transferred into skin cells with a single pulse of a High Voltage, followed, after a defined lag time, by a single pulse of Low Voltage.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the a3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies. A particular embodiment refers to the monoclonal antibody with the arbitrary designation 15E7 for which the sequence is provided. Also a anti-HLA-G single-chain antibody gene library was generated and six specific binders were identified from that library.

Abstract: The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a dog telomerase deprived of telomerase catalytic activity, or a fragment thereof.

Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Abstract: The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a dog telomerase deprived of telomerase catalytic activity, or a fragment thereof.

Abstract: The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof.

Abstract: The present invention relates to DNA expression vector or a mixture of DNA expression vectors which encodes at least two CD4 epitopes of telomerase reverse transcriptase (TERT) and at least one tumor, viral, bacterial, or parasitic CD8 epitope.

Abstract: The present invention relates to the use of a nucleic acid that comprises a sequence encoding an APOBEC3A protein, in preventing or treating a tumor in a patient.

Abstract: An antibody or antigen-binding fragment thereof which specifically binds the ?3 domain of a HLA-G protein, in particular binds the ?2-microglobulin free HLA-G protein exhibiting an ?3 domain. The nucleic acid molecules encoding a human HLA-G ?3 domain polypeptide, which is selected from a group of specific sequences, and vectors for the cloning and/or expression of such nucleic acid molecules, recombined cells or cell lines and compositions for use in a host in need thereof to interfere with and neutralize the immune down-regulation due to HLA-G proteins, and/or improving or treating conditions showing HLA-G+ lesions, and/or improving or treating a neoplasic condition or disease. A method of producing the antibody or antigen-binding fragment thereof, immunogenic compositions for use to elicit in a host an immune response against the ?3 domain of HLA-G protein, and an in vitro method for detecting HLA-G protein in a sample are also described.

Abstract: The present invention provides a nucleic acid, or an immunogenic composition thereof, that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof. The present invention also provides methods for triggering an immune response in a cat and methods for treating or preventing a tumor in a cat using the immunogenic composition of the invention.

Abstract: The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.

Abstract: The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.

Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Abstract: The present invention relates to the use of a nucleic acid that comprises a sequence encoding an APOBEC3A protein, in preventing or treating a tumor in a patient.

Abstract: The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof.